This post was originally published on this site
The U.S. Food and Drug Administration (FDA) scheduled last week an Oct. 15 meeting of its expert advisory committee to discuss whether to grant emergency use authorization for a booster shot of J&J (NYSE:JNJ)’s vaccine.
The regulator authorized a booster dose of the Pfizer Inc (NYSE:PFE) and partner BioNTech vaccine last month, for those 65 and older, people at high risk of severe disease, and others who are regularly exposed to the virus.
Rival Moderna (NASDAQ:MRNA) Inc also submitted its application seeking authorization for a booster shot of its two-dose vaccine last month.
J&J did not immediately respond to a Reuters request for comment.
